CF
ALXN

Copperwynd Financial’s Alexion Pharmaceuticals ALXN Stock Holding History

Copperwynd Financial’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,730
Closed -$685K – 129
2021
Q2 		$685K Buy
3,730
+15
+0.4% +$2.58K 0.29% 54
2021
Q1 		$568K Sell
3,715
-127
-3% -$19.6K 0.26% 63
2020
Q4 		$600K Sell
3,842
-253
-6% -$32.5K 0.29% 54
2020
Q3 		$469K Sell
4,095
-80
-2% -$8.63K 0.25% 66
2020
Q2 		$469K Sell
4,175
-391
-9% -$41.5K 0.27% 59
2020
Q1 		$410K Buy
4,566
+825
+22% +$81K 0.19% 51
2019
Q4 		$405K Sell
3,741
-454
-11% -$48.6K 0.21% 92
2019
Q3 		$453K Buy
+4,195
New +$473K 0.26% 88

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return